SZ - true point but how far do you have to go to prove the possibility of a nominal difference and would that be clinically meaningful. I believe that if the scope, scale and time committment of Oral Surveillance study were to be repeated 3-4 more times, we would likely have conflicting results. But thats just my opinion (sorta guided by the gout CONFIRMS and CARES data). Untill then, we only have these two studies to guide us as far as the safety of JAKi. We already know about the efficacy of JAKi - thanks to you and your colleagues!